Variant position: 380 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 522 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human DRAIDGLNLLPTLLQGRLMD RPIFYYRGDTLMAATLGQHKA
Mouse DRVIDGLDLLPTMLKGQMMD RPIFYYRGNTLMAVTLGQYKA
Rat DRVIDGLDLLPTMLQGHIID RPIFYYRGNTLMAVTLGQYKA
Pig DRAIDGLDLLPAMLQGRLTE RPIFYYRGNTLMAATLGQYKA
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
27 – 522 N-acetylgalactosamine-6-sulfatase
308 – 419
Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.
Morrone A.; Tylee K.L.; Al-Sayed M.; Brusius-Facchin A.C.; Caciotti A.; Church H.J.; Coll M.J.; Davidson K.; Fietz M.J.; Gort L.; Hegde M.; Kubaski F.; Lacerda L.; Laranjeira F.; Leistner-Segal S.; Mooney S.; Pajares S.; Pollard L.; Ribeiro I.; Wang R.Y.; Miller N.;
Mol. Genet. Metab. 112:160-170(2014)
Cited for: VARIANTS MPS4A GLU-16; ARG-36; ASN-40; GLY-48; LYS-51; ARG-77; LEU-80; LEU-81; GLU-84; TRP-90; PRO-91; CYS-94; LEU-94; PHE-113; VAL-116; SER-116; SER-139; ARG-141; TYR-145; LEU-151; ARG-155; LEU-156; ARG-166; SER-179; GLU-201; PRO-214; SER-216; GLY-230; ASN-233; LYS-235; THR-264; LEU-287; THR-291; CYS-301; SER-312; ARG-318; LEU-357; GLY-380; THR-380; CYS-386; HIS-386; VAL-391; VAL-392; HIS-407; VAL-415; THR-416; ARG-420; THR-492; VAL-494; SER-500 AND PHE-507; VARIANTS PHE-74; ASP-121; CYS-159; TYR-165; GLN-251; CYS-254; LYS-260 AND LYS-495; CHARACTERIZATION OF VARIANTS MPS4A GLU-16; ARG-36; LYS-51; LEU-81; GLU-84; PRO-91; VAL-116; TYR-145; LEU-156; ARG-166; GLU-201; PRO-214; SER-216; THR-264; GLY-380; VAL-415; THR-416; ARG-420; THR-492 AND SER-500;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.